Category: Patent Policy
-
Lose three validity battles, win the infringement war? Microsoft’s CNIPA record against Newman’s GUI patent
A long-running Chinese touchscreen patent dispute between Newman Infinite and Microsoft has now reached China’s Supreme People’s Court, after the latter failed in four patent invalidation attempts. But the record is less one-sided than it currently appears to be.
-
USITC seeks input on proposed new rules around real-party-in-interest disclosures
The proposed rulemaking fits with the trend seen across agencies dealing with U.S. patent matters, where there is a push for more transparency around real-parties-in-interest.
-
IPR petitions hit lowest-ever monthly total in April as new USPTO policies take hold
Meanwhile, requests for ex parte re-examination have skyrocketed to their highest number in years.
-
IP is the “basis of Europe’s competitiveness” – it would be “unrealistic” to think otherwise, says IP Europe’s new Secretary General Niklas Lagergren
“Our ideas and our intellectual property are basically the only possible basis we have for our future competitiveness,” Mr. Lagergren, who boasts 30 years in IP policy experience in Brussels, told ip fray in an exclusive interview.
-
China is “back” in SEP enforcement: CNIPA’s 2026 Working Scheme channels SEP disputes into administrative proceedings
The proceedings are a type of “Chinese featured ITC” venue offering three-month injunctions.
-
Google petitions U.S. Supreme Court over Patent Trial & Appeal Board “settled expectations” denials
Google’s petition is likely to attract amicus briefs from other companies that are finding it increasingly difficult to get inter partes reviews instituted.
-
BREAKING: China issues regulations countering foreign extraterritorial jurisdiction
The global ZTE v. Samsung FRAND rate-setting decision is potentially a targeted scenario.
-
USPTO Director Squires announces new ex parte reexamination measure to make patent revocation harder
The U.S. patent market has split reactions over the new process, which is designed to help the USPTO “efficiently and effectively” address the recent increased volume of ex parte reexamination requests.
-
USPTO Director Squires looks at PTAB IPR petitions through national security as well as economic policy (domestic manufacturing) lens
USPTO Director John A. Squires has recently issued a memorandum to PTAB users and a precedential denial of institution of an inter partes review. In either context, PTAB IPRs are put into a broader policy context.
-
Colombia pushes for compulsory licensing of U.S. pharma company’s patents
Colombia’s Health Minister has revived a previous administration’s investigation into four of U.S. pharma company Gilead’s patents at the core of Hepatitis-C treatment, issuing a public interest declaration to make the licensing of such patents compulsory.